Review article: the potential of combinational regimen with non‐steroidal anti‐inflammatory drugs in the chemoprevention of colorectal cancer
Open Access
- 2 February 2005
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 21 (4) , 321-339
Abstract
Non‐steroidal anti‐inflammatory drugs are chemopreventive agents in colorectal cancer. Non‐steroidal anti‐inflammatory drugs do not, however, offer complete protection against adenoma and carcinoma development. There is increasing interest in combining non‐steroidal anti‐inflammatory drugs with agents that target specific cell signalling pathways in malignant and premalignant cells. This review aims to describe the current knowledge regarding the efficacy of peroxisome proliferator‐activated receptor‐γ ligands, cholesterol synthesis inhibitors (statins), epidermal growth factor signalling inhibitors and tumour necrosis factor‐related apoptosis‐inducing ligand against colorectal neoplasms and the rationale for combining these drugs with non‐steroidal anti‐inflammatory drugs to improve efficacy in the chemoprevention of colorectal cancer, a PUBMED computer search of the English language literature was conducted to identify relevant papers published before July 2004. Peroxisome proliferator‐activated receptor‐γ ligands and statins, both in clinical use, reduce the growth rate of human colon cancer cells in vitro and in rodents models. In vitro , preclinical in vivo and clinical studies have shown efficacy of epidermal growth factor signalling inhibition in colorectal cancer. In vitro , tumour necrosis factor‐related apoptosis‐inducing ligand induces apoptosis in human colon cancer cells, but not in normal cells. These drugs have all been shown to interact with non‐steroidal anti‐inflammatory drugs in colorectal cancer cells and/or in rodent models. Combinational regimen are a promising strategy for the chemoprevention of colorectal cancer and should be further explored.Keywords
This publication has 158 references indexed in Scilit:
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell linesBritish Journal of Cancer, 2003
- HER 2/neu expression and gene amplification in colon cancerInternational Journal of Cancer, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasNew England Journal of Medicine, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal CancerNew England Journal of Medicine, 2003
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosisLeukemia, 2002
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Terminal Differentiation of Human Breast Cancer through PPARγMolecular Cell, 1998
- Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study GroupJAMA, 1996
- Randomised study of screening for colorectal cancer with faecal-occult-blood testThe Lancet, 1996